These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9633754)

  • 1. Mood response to levodopa infusion in early Parkinson's disease.
    Maricle RA; Valentine RJ; Carter J; Nutt JG
    Neurology; 1998 Jun; 50(6):1890-2. PubMed ID: 9633754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa changes the severity of freezing in Parkinson's disease.
    Fietzek UM; Zwosta J; Schroeteler FE; Ziegler K; Ceballos-Baumann AO
    Parkinsonism Relat Disord; 2013 Oct; 19(10):894-6. PubMed ID: 23642712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study.
    Maricle RA; Nutt JG; Valentine RJ; Carter JH
    Neurology; 1995 Sep; 45(9):1757-60. PubMed ID: 7675241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease.
    Black KJ; Hershey T; Hartlein JM; Carl JL; Perlmutter JS
    Neuropsychopharmacology; 2005 Mar; 30(3):590-601. PubMed ID: 15602502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa has mood-enhancing effects in healthy elderly adults.
    Vo A; Ganjavi H; MacDonald PA
    Int J Geriatr Psychiatry; 2018 Apr; 33(4):674-675. PubMed ID: 29498779
    [No Abstract]   [Full Text] [Related]  

  • 7. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.
    Maricle RA; Nutt JG; Carter JH
    Mov Disord; 1995 May; 10(3):329-32. PubMed ID: 7651451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
    Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
    Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of duloxetine on motor and mood symptoms in Parkinson's disease: An open-label clinical experience.
    Nishijima H; Ueno T; Kon T; Haga R; Funamizu Y; Arai A; Suzuki C; Nunomura JI; Baba M; Tomiyama M
    J Neurol Sci; 2017 Apr; 375():186-189. PubMed ID: 28320128
    [No Abstract]   [Full Text] [Related]  

  • 13. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
    Gerschlager W; Bloem BR
    Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
    Metman LV; van den Munckhof P; Klaassen AA; Blanchet P; Mouradian MM; Chase TN
    Neurology; 1997 Sep; 49(3):711-3. PubMed ID: 9305328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The variability of levodopa response in Parkinson's disease: is sensitization reversible?
    Jabre MG; Bejjani BP
    Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452
    [No Abstract]   [Full Text] [Related]  

  • 16. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
    Schuh LA; Bennett JP
    Neurology; 1993 Aug; 43(8):1545-50. PubMed ID: 8351009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classics in chemical neuroscience: levodopa.
    Whitfield AC; Moore BT; Daniels RN
    ACS Chem Neurosci; 2014 Dec; 5(12):1192-7. PubMed ID: 25270271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daily motor performance after switching levodopa to melevodopa: an open-label on advanced Parkinson's disease with "delayed-on" and/or"wearing-off".
    Bosco D; Plastino M; Bosco F; Fava A; Rotondo A
    Minerva Med; 2011 Apr; 102(2):125-32. PubMed ID: 21483399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
    Santos-García D; Macías M; Llaneza M; Fuster-Sanjurjo L; Echarri-Piudo A; Belmonte S; Blanco S
    Neurologia; 2010; 25(9):536-43. PubMed ID: 21093702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.